Clinical Trial Update: Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating nivolumab plus ABI-009 (nab-rapamycin) in patients with advanced sarcoma and selected cancers, with results posted for a compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chordoma
• Desmoid Tumor
• Epithelioid Sarcoma
• Ewing Sarcoma
• Melanoma
• Non-small Cell Lung Cancer
• Pecoma
• Urothelial Carcinoma

Drugs mentioned

• Nab-rapamycin (ABI-009) (nab-rapamycin)
• nivolumab (nivolumab)

Snippet

Sponsor: Sarcoma Oncology Research Center, LLC | Conditions: Ewing Sarcoma, PEComa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-17